Premium
Clinical data, clinicopathologic findings and outcome in dogs with amegakaryocytic thrombocytopenia and primary immune‐mediated thrombocytopenia
Author(s) -
Cooper S. A.,
Huang A. A.,
Raskin R. E.,
Weng H.Y.,
ScottMoncrieff J. C.
Publication year - 2016
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/jsap.12441
Subject(s) - medicine , immune thrombocytopenia , immune system , clinical significance , peripheral , bone marrow , peripheral blood , immunology , antibody
OBJECTIVES The aim of this study was to identify distinguishing characteristics between dogs diagnosed with amegakaryocytic thrombocytopenia and those diagnosed with presumed primary peripheral immune‐mediated thrombocytopenia. Presenting clinical and clinicopathologic data and outcomes were compared between the two groups. METHODS Retrospective study performed on seven client‐owned dogs diagnosed with amegakaryocytic thrombocytopenia and 34 client‐owned dogs with primary peripheral immune‐mediated thrombocytopenia. RESULTS All dogs in the amegakaryocytic thrombocytopenia group were anaemic on presentation with a median haematocrit of 23% (range 9·4 to 36), while the primary peripheral immune‐mediated thrombocytopoenia group had a median presenting haematocrit of 35% (range 10 to 53). Dogs with amegakaryocytic thrombocytopenia had a median of five (range 4 to 7) clinical signs of bleeding compared to a median of three (range 0 to 6) in the primary peripheral immune‐mediated thrombocytopenia group with 86% (6 of 7) of amegakaryocytic thrombocytopenia dogs requiring a blood transfusion compared to 41% (14 of 34) of primary peripheral immune‐mediated thrombocytopenia dogs. Six of the seven amegakaryocytic thrombocytopenia dogs did not survive to discharge, while only five of the 34 primary peripheral immune‐mediated thrombocytopenia dogs did not survive to discharge. CLINICAL SIGNIFICANCE The clinical presentation of dogs with amegakaryocytic thrombocytopenia and primary peripheral immune‐mediated thrombocytopenia is similar, but dogs with amegakaryocytic thrombocytopenia had a more severe clinical course compared to primary peripheral immune‐mediated thrombocytopenia dogs. The prognosis for dogs with amegakaryocytic thrombocytopenia is poor.